<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v =2.1 7.9.post6+86293ac&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20230823081430&amp;utm_source=Chrome&amp;utm_campaign=pubmed -2<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20230823081430&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 23 日星期三 12:14:32 +0000</lastbuilddate><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>异常的淋巴鞘氨醇-1-磷酸信号传导会加剧淋巴功能障碍和组织炎症</title><link/>https://pubmed.ncbi.nlm.nih.gov/37609838/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>结论：这项研究表明，LEC S1P 信号传导的减少通过增强 LEC 粘附和放大致病性 CD4 T 细胞反应而加重淋巴水肿。P-选择素抑制剂被建议作为这种普遍病症的可能治疗方法。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 23 日。doi：10.1161/CIRCULATIONAHA.123.064181。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：淋巴水肿是一个全球性的健康问题，目前尚无有效的药物治疗方法。增强的 T 细胞免疫力和异常的淋巴内皮细胞 (LEC) 信号传导是该疾病有希望的治疗靶点。1-磷酸鞘氨醇 (S1P) 介导所需的关键信号通路对于正常的 LEC 功能，LEC 中 S1P 信号传导的改变可能导致淋巴疾病和致病性 T 细胞激活。表征这种生物学特征对于开发急需的疗法相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：研究人和小鼠淋巴水肿。通过手术结扎尾部淋巴管在小鼠中诱导淋巴水肿。评估淋巴水肿真皮组织的 S1P 信号传导。为了验证改变的 S1P 信号传导效应在淋巴细胞中的作用，LEC 特异性<i>S1pr1</i>缺陷（随着时间的推移，通过尾部体积和组织病理学测量来量化疾病进展。来自小鼠和<sup>人类</sup>的<i>LEC</i> ，具有 S1P 信号传导抑制，然后与 CD4 T 细胞共培养，然后分析 CD4 T 细胞激活和通路信号传导。用 P-选择素特异性单克隆抗体治疗动物，以评估其减少淋巴水肿和 T 细胞活化的功效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：人类和实验性淋巴水肿组织通过 S1P 受体 1 (S1PR1) 证明了 LEC S1P 信号传导。LEC <i>S1pr1</i>功能丧失加剧了小鼠淋巴水肿中的淋巴血管功能不全、尾部肿胀减少以及 CD4 T 细胞浸润增加。 <i>S1pr1</i> <sup>LECKO</sup>小鼠与 CD4 T 细胞共培养，导致淋巴细胞分化增强。抑制人真皮 LEC 中的 S1PR1 信号传导，通过与淋巴细胞直接接触促进 T 辅助细胞 1 型和 2 型（Th1 和 Th2）细胞分化。人真皮 LEC 受到抑制S1P 信号传导显示增强的 P-选择素（一种在活化血管细胞上表达的重要细胞粘附分子）。在体外，P-选择素阻断可减少与<i>shS1PR1</i>处理的人真皮 LEC 共培养的 Th 细胞的活化和分化。改善尾部并减少 Th1/ 肿胀小鼠淋巴水肿中的 Th2 免疫反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究表明，LEC S1P 信号传导的减少通过增强 LEC 粘附和放大致病性 CD4 T 细胞反应而加重淋巴水肿。P-选择素抑制剂被建议作为这种普遍病症的可能治疗方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37609838/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37609838</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064181>10.1161/CIRCULATIONAHA.123.064181</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37609838</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>金东健</dc:creator><dc:creator>文田</dc:creator><dc:creator>吴廷轩</dc:creator><dc:creator>梦兰乡</dc:creator><dc:creator>瑞安·文恩</dc:creator><dc:creator>——贾森·朗·张</dc:creator><dc:creator>谷申彪</dc:creator><dc:creator>李升熙</dc:creator><dc:creator>于朱</dc:creator><dc:creator>Torreyguan更多</dc:creator><dc:creator>埃米莉·克莱尔·施奈德</dc:creator><dc:creator>Evan Bao更多</dc:creator><dc:creator>J·布兰登·迪克森</dc:creator><dc:creator>Peter Kao更多</dc:creator><dc:creator>潘俊良</dc:creator><dc:creator>——斯坦利·洛克森</dc:creator><dc:creator>蒋新国</dc:creator><dc:creator>——马克·罗伯特·尼科尔斯</dc:creator><dc:date>2023-08-23</dc:date><dc:source>循环</dc:source><dc:title>异常的淋巴鞘氨醇-1-磷酸信号传导会加剧淋巴功能障碍和组织炎症</dc:title><dc:identifier>下午：37609838</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064181</dc:identifier></item><item><title>房性和室性心律失常的长期风险：“癫痫性心脏”的主要表现</title><link/>https://pubmed.ncbi.nlm.nih.gov/37608403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 22 日：ehad524。doi：10.1093/eurheartj/ehad524。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37608403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37608403</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad524>10.1093/eurheartj/ehad524</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37608403</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——理查德·L·维里尔</dc:creator><dc:creator>彭楚迪</dc:creator><dc:creator>史蒂文·C·沙赫特</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>房性和室性心律失常的长期风险：“癫痫性心脏”的主要表现</dc:title><dc:identifier>下午：37608403</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad524</dc:identifier></item><item><title>线虫跨多个时间尺度和状态的全脑行为表征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37607537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>动物行为和内部状态的变化伴随着自由移动的秀丽隐杆线虫大脑活动的广泛变化，并建立了概率模型来解释每个神经元如何编码定量行为特征。通过确定记录的神经元的身份，我们创建了一本关于……的地图集</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 14 日：S0092-8674(23)00850-4.doi: 10.1016/j.cell.2023.07.035. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">动物行为和内部状态的变化伴随着自由移动的秀丽隐杆线虫大脑活动的广泛变化，并建立了概率模型来解释每个神经元如何编码定量行为特征。通过确定记录的神经元的身份，我们创建了线虫连接组中定义的神经元类别如何编码行为的图谱。此外，尽管许多神经元编码当前的运动动作，但其他神经元则整合最近的动作。行为状态的变化伴随着神经元编码行为方式的广泛变化，我们确定连接组中的这些灵活节点提供了动物大脑中的细胞类型如何编码其行为的全局图。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37607537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37607537</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.035>10.1016/j.cell.2023.07.035</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37607537</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>亚当·阿塔纳斯</dc:creator><dc:creator>金正洙</dc:creator><dc:creator>王子玉</dc:creator><dc:creator>埃里克·布埃诺 (Eric Bueno)</dc:creator><dc:creator>麦考伊·贝克尔</dc:creator><dc:creator>迪康</dc:creator><dc:creator>朴正渊</dc:creator><dc:creator>塔利亚·克莱默</dc:creator><dc:creator>温芙蓉</dc:creator><dc:creator>萨巴巴斯科伊鲁</dc:creator><dc:creator>Ugur Dag更多</dc:creator><dc:creator>埃尔皮尼基·卡洛格罗普鲁</dc:creator><dc:creator>——马修·A·戈麦斯</dc:creator><dc:creator>卡西·埃斯特雷姆</dc:creator><dc:creator>内塔·科恩</dc:creator><dc:creator>Vikash K Mansinghka更多</dc:creator><dc:creator>——史蒂文·W·弗拉维尔</dc:creator><dc:date>2023-08-22</dc:date><dc:source>细胞</dc:source><dc:title>线虫跨多个时间尺度和状态的全脑行为表征</dc:title><dc:identifier>下午：37607537</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.035</dc:identifier></item><item><title>人类自然杀伤细胞的泛癌单细胞全景图</title><link/>https://pubmed.ncbi.nlm.nih.gov/37607536/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>自然杀伤 (NK) 细胞在对抗肿瘤进展的先天免疫反应中发挥着不可或缺的作用。为了描述其在肿瘤微环境中的表型和功能多样性，我们对来自 716 名癌症患者的 NK 细胞进行了综合单细胞 RNA 测序分析，涵盖了 24 种癌症类型。我们以肿瘤类型特异性的方式观察到 NK 细胞组成的异质性。值得注意的是，我们已经鉴定出一组在肿瘤中富集的肿瘤相关 NK 细胞，显示... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 15 日：S0092-8674(23)00849-8.doi: 10.1016/j.cell.2023.07.034.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">自然杀伤 (NK) 细胞在对抗肿瘤进展的先天免疫反应中发挥着不可或缺的作用。为了描述其在肿瘤微环境中的表型和功能多样性，我们对来自 716 名癌症患者的 NK 细胞进行了综合单细胞 RNA 测序分析，涵盖了 24 种癌症我们以肿瘤类型特异性的方式观察了 NK 细胞组成的异质性。值得注意的是，我们鉴定了一组肿瘤相关 NK 细胞，它们在肿瘤中富集，表现出抗肿瘤功能受损，并与不良预后相关。骨髓细胞亚群，特别是 LAMP3 <sup>+</sup>树突状细胞，似乎介导 NK 细胞抗肿瘤免疫的调节。我们的研究提供了对基于 NK 细胞的癌症免疫的见解，并强调了 NK 细胞亚群作为治疗靶点的潜在临床用途。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37607536/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37607536</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.034>10.1016/j.cell.2023.07.034</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37607536</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>唐飞</dc:creator><dc:creator>李金虎</dc:creator><dc:creator>陆奇</dc:creator><dc:creator>刘东方</dc:creator><dc:creator>薄宇飞</dc:creator><dc:creator>秦世尚</dc:creator><dc:creator>苗玉辉</dc:creator><dc:creator>于克卓</dc:creator><dc:creator>侯文宏</dc:creator><dc:creator>李嘉楠</dc:creator><dc:creator>彭继润</dc:creator><dc:creator>田志刚</dc:creator><dc:creator>朱林南</dc:creator><dc:creator>彭慧</dc:creator><dc:creator>王东方</dc:creator><dc:creator>张泽民</dc:creator><dc:date>2023-08-22</dc:date><dc:source>细胞</dc:source><dc:title>人类自然杀伤细胞的泛癌单细胞全景图</dc:title><dc:identifier>下午：37607536</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.034</dc:identifier></item><item><title>抗血栓治疗：个性化抗血小板治疗和肠道菌群的教训</title><link/>https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 8 月 22 日；44(32):3023-3026.doi: 10.1093/eurheartj/ehad521。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37607038</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad521>10.1093/eurheartj/ehad521</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37607038</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-08-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>抗血栓治疗：个性化抗血小板治疗和肠道菌群的教训</dc:title><dc:identifier>下午：37607038</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad521</dc:identifier></item><item><title>将患者报告的结果置于心血管临床实践的中心：对护理和管理质量的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>患者报告结果 (PRO) 为了解患者对自身健康和医疗状况的看法提供了重要见解，并且有证据表明，它们的使用可以改善护理质量并做出更明智的临床决策。过去几十年。该声明描述了 PRO 是什么，并提供了针对心血管疾病开发的特定疾病和特定领域 PRO 的清单…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 22 日：ehad514。doi：10.1093/eurheartj/ehad514。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">患者报告结果 (PRO) 为了解患者对自身健康和医疗状况的看法提供了重要见解，并且有证据表明，它们的使用可以改善护理质量并做出更明智的临床决策。该声明描述了 PRO 是什么，并提供了针对心血管人群开发的针对特定疾病和特定领域的 PRO 的清单。国际标准和质量指数已经发布，可以指导针对心血管人群的 PRO 的选择。临床实践以及临床试验和研究；患者以及心理测量学专家应参与选择最合适的方案。需要合作来定义使用 PRO 来指导监管决策的标准，以及 PRO 比较和监测的效用应该评估护理质量和资源分配。记录 PRO 的新来源包括可穿戴数字健康设备、医疗登记和电子健康记录。为心血管医学共享临床决策中 PRO 的最佳使用提供建议，以及关于其更广泛应用的未来方向。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37606064</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad514>10.1093/eurheartj/ehad514</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37606064</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>菲利普·穆恩斯</dc:creator><dc:creator>托恩·M·诺雷克瓦尔</dc:creator><dc:creator>埃琳娜·阿贝洛</dc:creator><dc:creator>布里特·博雷加德</dc:creator><dc:creator>芭芭拉·卡萨迪</dc:creator><dc:creator>伯纳德·科辛斯</dc:creator><dc:creator>马丁·R·考伊</dc:creator><dc:creator>唐娜·菲茨西蒙斯</dc:creator><dc:creator>艾伦·弗雷泽</dc:creator><dc:creator>小贾斯玛</dc:creator><dc:creator>保卢斯·基希霍夫</dc:creator><dc:creator>何塞帕·毛里</dc:creator><dc:creator>——理查德·明德姆</dc:creator><dc:creator>朱莉·桑德斯</dc:creator><dc:creator>弗朗索瓦·席勒</dc:creator><dc:creator>亚历山大·托比卡</dc:creator><dc:creator>——安·多尔特·兹维斯勒</dc:creator><dc:date>2023-08-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>将患者报告的结果置于心血管临床实践的中心：对护理和管理质量的影响</dc:title><dc:identifier>下午：37606064</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad514</dc:identifier></item><item><title>大脑 α2δ-1 结合 NMDA 受体驱动钙调神经磷酸酶抑制剂诱发的高血压</title><link/>https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>结论：这些发现表明，α2δ-1 对于钙调神经磷酸酶抑制剂诱导的 PVN 前交感神经元和交感神经流出突触 NMDAR 活性的增加至关重要。因此，α2δ-1 和 α2δ-1 结合的 NMDAR 代表了治疗钙调神经磷酸酶抑制剂诱导的突触 NMDAR 活性的新靶点。高血压。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 22 日。doi：10.1161/CIRCRESAHA.123.322562。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：钙调磷酸酶在免疫 T 细胞和神经系统中高度富集。钙调磷酸酶抑制剂，包括环孢素和他克莫司 (FK506)，是保护移植器官和组织的免疫抑制方案的基石。过量的交感神经流出，由 N- 维持甲基-D-天冬氨酸受体 (NMDAR) 介导的下丘脑室旁核 (PVN) 兴奋性输入。目前尚不清楚钙调神经磷酸酶抑制剂如何增加 PVN 中的 NMDAR 活性以增强交感血管舒缩活性。α2δ-1（由<i>Cacna2d1</i>基因编码）通俗地称为钙通道亚基，是一种新发现的 NMDAR 相互作用蛋白。在这里，我们确定了 α2δ-1 是否在钙调磷酸酶抑制剂诱导的 PVN 和高血压发展中的突触 NMDAR 过度活跃中发挥作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：免疫印迹和免疫共沉淀分析表明，长期使用 FK506 治疗大鼠可显着增加 PVN 突触体中 α2δ-1、GluN1（必需的 NMDAR 亚基）和 α2δ-1-GluN1 复合物的蛋白水平。加巴喷丁或中断 α2δ-1-NMDAR 与 α2δ-1 C 末端肽的相互作用。脑切片中的全细胞记录表明，FK506 治疗增强了脊髓投射 PVN 神经元中突触前和突触后 NMDAR 的活性，这种作用被消除加巴喷丁、 <i>Cacna2d1</i>敲除或 α2δ-1 C 末端肽。值得注意的是，遥测记录表明，同时给予加巴喷丁可预防 FK506 诱导的大鼠高血压的发生。此外，FK506 治疗可在野生型小鼠中诱导持续性高血压，但在野生型小鼠中则不然。 <i>Cacna2d1</i>基因敲除小鼠。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现表明，α2δ-1 对于钙调神经磷酸酶抑制剂诱导的 PVN 前交感神经元和交感神经流出突触 NMDAR 活性的增加至关重要。因此，α2δ-1 和 α2δ-1 结合的 NMDAR 代表了治疗钙调神经磷酸酶抑制剂诱导的突触 NMDAR 活性的新靶点。高血压。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37605933</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322562>10.1161/CIRCRESAHA.123.322562</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37605933</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>周晶晶</dc:creator><dc:creator>邵建英</dc:creator><dc:creator>陈少瑞</dc:creator><dc:creator>潘慧琳</dc:creator><dc:date>2023-08-22</dc:date><dc:source>流通研究</dc:source><dc:title>大脑 α2δ-1 结合 NMDA 受体驱动钙调神经磷酸酶抑制剂诱发的高血压</dc:title><dc:identifier>下午：37605933</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322562</dc:identifier></item><item><title>盐皮质激素受体拮抗剂联合钠-葡萄糖协同转运蛋白 2 抑制剂治疗心力衰竭：一项荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>结论：MRA 并不影响 SGLT2i 对 HHF/CVD、HHF 或全因死亡率的综合影响；然而，研究结果暗示，慢性心力衰竭患者的 CVD 相对降低更为显着，无论 EF 的情况如何，这些患者被随机分配到 SGLT2i 组并接受MRA 与那些随机接受 SGLT2i 且未接受 MRA 的患者相比。SGLT2i 降低了 MRA 相关治疗引起的高钾血症的风险。这些发现值得在精心设计的随机对照试验中得到进一步验证。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 22 日：ehad522。doi：10.1093/eurheartj/ehad522。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：研究钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 与盐皮质激素受体拮抗剂 (MRA) 联合使用对心力衰竭 (HF) 的心血管影响，无论射血分数 (EF) 如何，并探讨 MRA 的风险随机接受 SGLT2i 与安慰剂组的个体的相关不良事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在 PubMed/MEDLINE、Web of Science、Embase 和临床试验注册中心中搜索评估 SGLT2i 在使用或不使用 MRA 的情况下治疗心力衰竭的随机对照试验/事后分析（PROSPERO：CRD42023397129）。或因心力衰竭/心血管死亡而紧急就诊(HHF/CVD)、HHF 和 CVD。其他为全因死亡率、复合肾脏和安全性结果。提取风险比 (HR)/风险比。进行固定效应荟萃分析和亚组分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：纳入了五项符合条件的研究，汇集了 21 947 名 HF 患者（2 型糖尿病，n = 10 805）的数据。与安慰剂相比，SGLT2i 的随机分组显示，患有或患有 HF 的患者的 HHF/CVD 和 HHF 有类似的减少。未使用 MRA [HHF/CVD：风险比 (HR) 0.75；95% 置信区间 (CI) 0.68-0.81 vs. HR 0.79；95% CI 0.72-0.86；P 交互作用 = 0.43；HHF：HR 0.74； 95% CI 0.67-0.83 对比 HR 0.71；95% CI 0.63-0.80；P 交互作用 = .53]，这表明随机接受 SGLT2i 并使用 MRA 的慢性心力衰竭患者的 CVD 相对减少较多，与 EF 无关（HR 95% CI 0.72-0.91 对比 HR 0.98；95% CI 0.86-1.13；P 相互作用 = .034）。SGLT2i 降低全因死亡率（P 相互作用 = .27）和不良肾脏终点，无论 MRA 使用情况如何 SGLT2i 减弱轻度高钾血症（P-相互作用 &lt; .001）和重度高钾血症（P-相互作用 = .001）的风险，尽管与 MRA 使用相关的伴随 MRA 容量不足的风险较高（P-相互作用 = .082）。0.051） 。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：MRA 并不影响 SGLT2i 对 HHF/CVD、HHF 或全因死亡率的综合影响；然而，研究结果暗示，慢性心力衰竭患者的 CVD 相对降低更为显着，无论 EF 的情况如何，这些患者被随机分配到 SGLT2i 组并接受MRA 与那些随机接受 SGLT2i 且未接受 MRA 的患者相比。SGLT2i 降低了 MRA 相关治疗引起的高钾血症的风险。这些发现值得在精心设计的随机对照试验中进一步验证。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37605637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37605637</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad522>10.1093/eurheartj/ehad522</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37605637</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator>迈纳克·班纳吉</dc:creator><dc:creator>英迪拉·迈斯南</dc:creator><dc:creator>里梅什·帕尔</dc:creator><dc:creator>萨蒂娜·穆霍帕迪亚</dc:creator><dc:date>2023-08-22</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>盐皮质激素受体拮抗剂联合钠-葡萄糖协同转运蛋白 2 抑制剂治疗心力衰竭：一项荟萃分析</dc:title><dc:identifier>下午：37605637</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad522</dc:identifier></item><item><title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):e8.doi: 10.1161/CIR.0000000000001177. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603606/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37603606</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001177>10.1161/CIR.0000000000001177</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603606</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:date> 2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</dc:title><dc:identifier>下午：37603606</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001177</dc:identifier></item><item><title>二叶式主动脉瓣和胸主动脉疾病：临床上对受影响个体的家庭成员无声但致命的风险的进一步证据</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):648-650. doi: 10.1161/CIRCULATIONAHA.123.06540​​6. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37603605</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065406>10.1161/CIRCULATIONAHA.123.06540​​6</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603605</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>悉达多·K·普拉卡什</dc:creator><dc:creator>赫克托一世·米凯莱娜</dc:creator><dc:creator>戴安娜·米勒维奇</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>二叶式主动脉瓣和胸主动脉疾病：临床上对受影响个体的家庭成员无声但致命的风险的进一步证据</dc:title><dc:identifier>下午：37603605</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.06540​​6</dc:identifier></item><item><title>心脏移植分子诊断的选择和解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>美国和全世界每年进行的心脏移植手术数量持续增加，但过去 20 年来移植物寿命和患者生存率几乎没有变化。诊断急性细胞和抗体介导的排斥反应的参考标准包括组织学检查心内膜心肌活检样本的免疫荧光评估和免疫荧光评估，尽管组织学排斥反应分级具有侵入性和较高的受试者间变异性。循环生物标志物和... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):679-694. doi: 10.1161/CIRCULATIONAHA.123.062847. Epub 2023 年 8 月 21 日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">美国和全世界每年进行的心脏移植手术数量持续增加，但过去 20 年来移植物寿命和患者生存率几乎没有变化。诊断急性细胞和抗体介导的排斥反应的参考标准包括组织学检查心内膜心肌活检样本的免疫荧光评估，尽管具有侵入性和对组织学排斥进行分级的高人间变异性。循环生物标志物和分子诊断在排斥监测中显示出巨大的预测价值，并且新出现的数据支持它们在诊断其他移植后并发症中的使用。无细胞DNA） 、转录组学（mRNA 和 microRNA 分析）和蛋白质组学（蛋白质表达定量）方法诊断这些移植后结果已通过不同程度的证据进行了评估。排斥（免疫遗传学）增强了对抗体介导的排斥、相关移植物功能障碍和死亡。针对供者人类白细胞抗原的抗体以及可用于评估这些抗体的技术不断发展。用于诊断移植后并发症。这包括对儿科心脏移植的讨论以及接受心脏移植的黑人患者经历的不同的排斥率和死亡率. 这篇综述描述了移植后可用和使用的诊断方式，以及提高移植后患者预后所需的未来研究前景。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37603604</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.062847>10.1161 / CIRCULATIONAHA.123.062847</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603604</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——贾森·F·戈德堡</dc:creator><dc:creator>劳伦·特鲁比</dc:creator><dc:creator>肖恩·阿格博-伊诺</dc:creator><dc:creator>——安妮特·M·杰克逊</dc:creator><dc:creator>克里斯托弗·R·德菲利皮</dc:creator><dc:creator>Kiran K Khush更多</dc:creator><dc:creator>帕拉克·沙阿</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>心脏移植分子诊断的选择和解释</dc:title><dc:identifier>下午：37603604</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.062847</dc:identifier></item><item><title>乙醇诱发的心房颤动由晚期 &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; 引起，可用雷诺嗪预防</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):698-700. doi: 10.1161/CIRCULATIONAHA.123.064561. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603603/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37603603</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064561>10.1161 / CIRCULATIONAHA.123.064561</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603603</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱利安·穆斯特罗夫</dc:creator><dc:creator>玛丽亚·J·拜尔</dc:creator><dc:creator>丹尼斯·温辛</dc:creator><dc:creator>兹德内克·普罗瓦兹尼克</dc:creator><dc:creator>科斯坦丁·科扎科夫</dc:creator><dc:creator>西蒙·勒贝克</dc:creator><dc:creator>丹尼尔·塔尔诺夫斯基</dc:creator><dc:creator>松克·希尔特</dc:creator><dc:creator>尼尔斯·沃伊特</dc:creator><dc:creator>斯特凡·瓦格纳</dc:creator><dc:creator>拉斯·迈尔</dc:creator><dc:creator>斯特凡·尼夫</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>乙醇诱发的心房颤动由晚期 &lt;em>;I&lt;/em>;&lt;sub>;Na&lt;/sub>; 引起，可用雷诺嗪预防</dc:title><dc:identifier>下午：37603603</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064561</dc:identifier></item><item><title> Teng 等人关于文章“肠道微生物衍生的三甲胺 N-氧化物通过炎症和凋亡机制导致腹主动脉瘤”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):701-702. doi: 10.1161/CIRCULATIONAHA.123.065557. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37603602</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065557>10.1161/CIRCULATIONAHA.123.065557</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603602</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>滕振清</dc:creator><dc:creator>向马</dc:creator><dc:creator>马一桐</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>Teng 等人关于文章“肠道微生物衍生的三甲胺 N-氧化物通过炎症和凋亡机制导致腹主动脉瘤”的信函</dc:title><dc:identifier>下午：37603602</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065557</dc:identifier></item><item><title>排尿晕厥……并不总是良性的</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603601/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):695-697. doi: 10.1161/CIRCULATIONAHA.123.066038. Epub 2023 年 8 月 21 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603601/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37603601</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066038>10.1161 / CIRCULATIONAHA.123.066038</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603601</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>穆尼姆·阿里·汗</dc:creator><dc:creator>萨米·维斯金</dc:creator><dc:creator>克里斯托弗·马迪亚斯</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>排尿晕厥……并不总是良性的</dc:title><dc:identifier>下午：37603601</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066038</dc:identifier></item><item><title>心肾生物标志物、卡格列净和糖尿病肾病的结果：CREDENCE 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37603600/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823081430&amp;v=2.17.9.post6+86293ac<description>结论：多种心肾应激生物标志物对患有 2 型糖尿病和白蛋白尿的患者具有很强的预后作用。卡格列净适度降低了每种生物标志物上升的纵向轨迹。除基线水平外，生物标志物水平的变化增强了主要结果预测。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 22 日；148(8):651-660. doi: 10.1161/CIRCULATIONAHA.123.065251. Epub 2023 年 8 月 21 日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：患有蛋白尿的 2 型糖尿病患者发生心脏和肾脏事件的风险较高。帮助疾病预测和了解钠-葡萄糖协同转运蛋白 2 抑制的益处的最佳生物标志物仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在 CREDENCE 试验（卡格列净和糖尿病肾病临床评估中的肾脏事件）的 2627 名研究参与者中，检测 NT-proBNP（N 末端 B 型利钠肽前体）浓度、高敏心肌肌钙蛋白 T、生长情况测量分化因子-15和IGFBP7（胰岛素样生长因子结合蛋白7）。评估卡格列净对生物标志物浓度的影响。透析、移植或持续估计肾小球滤过率&lt;15 mL min <sup>-1</sup> 1.73 m <sup>-2</sup> ]，血清肌酐水平加倍，或肾死亡或心血管死亡）进行了评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：每种生物标志物的中位（四分位数 1 和 3）浓度普遍升高：NT-proBNP，180 ng/L (82, 442 ng/L)；高敏心肌肌钙蛋白 T，19 ng/L (12, 29 ng/L)；生长分化因子-15，2595 ng/L (1852, 3775 ng/L)；IGFBP7，121.8 ng/mL (105.4, 141.5 ng/mL)。1 年时，生物标志物均上升 6安慰剂组中的 % 至 29%，但卡格列净组中仅为 3% 至 10%（多变量线性混合效应模型中所有<i>P</i> &lt;0.01）。每种生物标志物的基线浓度对心脏和肾脏结果具有很强的预测作用。在多标志物面板中对具有高风险评分（风险比 [HR]，4.01 [95% CI，2.52-6.35]）和中等风险评分（HR，2.39 [95% CI，1.48-3.87]）的个体进行一起分析。与低风险评分的患者相比，主要结局的风险更高。到 1 年，NT-proBNP (HR, 1.11 [95% CI, 1.08-1.15])、高敏心肌肌钙蛋白 T ( HR ，1.86 [95% CI，1.64-2.10]）、生长分化因子 15（HR，1.45 [95% CI，1.24-1.70]）和 IGFBP7（HR，3.76 [95% CI，2.54-5.56]）与主要结局的风险相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：多种心肾应激生物标志物对患有 2 型糖尿病和白蛋白尿的患者具有很强的预后作用。卡格列净适度降低了每种生物标志物上升的纵向轨迹。除基线水平外，生物标志物水平的变化增强了主要结果预测。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT02065791。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37603600/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37603600</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065251>10.1161/CIRCULATIONAHA.123.065251</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37603600</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator>詹姆斯·贾努齐</dc:creator><dc:creator>礼萨·莫赫比</dc:creator><dc:creator>刘玉玺</dc:creator><dc:creator>纳维德·萨塔尔</dc:creator><dc:creator>希多·JL·赫尔斯平克</dc:creator><dc:creator>埃谢图·泰费拉</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>Yshai Yavin更多</dc:creator><dc:creator>李经纬</dc:creator><dc:creator>卡罗尔·波洛克</dc:creator><dc:creator>弗拉多·佩尔科维奇</dc:creator><dc:creator>布鲁斯·尼尔</dc:creator><dc:creator>——迈克尔·K·汉森</dc:creator><dc:date>2023-08-21</dc:date><dc:source>循环</dc:source><dc:title>心肾生物标志物、卡格列净和糖尿病肾病的结果：CREDENCE 试验</dc:title><dc:identifier>下午：37603600</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065251</dc:identifier></item><item><title>使用单一新型腺相关病毒提供的优化心脏重编程混合物改善缺血后大鼠的心脏功能</title><link/>https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823081430&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Collectively, these results advance the application of cardiac reprogramming gene therapy as a viable therapeutic approach to treat chronic heart failure resulting from ischemic injury. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 21. doi: 10.1161/CIRCULATIONAHA.122.061542. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Cardiac reprogramming is a technique to directly convert nonmyocytes into myocardial cells using genes or small molecules. This intervention provides functional benefit to the rodent heart when delivered at the time of myocardial infarction or activated transgenically up to 4 weeks after myocardial infarction. Yet, several hurdles have prevented the advancement of cardiac reprogramming for clinical use. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Through a combination of screening and rational design, we identified a cardiac reprogramming cocktail that can be encoded in a single adeno-associated virus. We also created a novel adeno-associated virus capsid that can transduce cardiac fibroblasts more efficiently than available parental serotypes by mutating posttranslationally modified capsid residues. Because a constitutive promoter was needed to drive high expression of these cell fate-altering reprogramming factors, we included binding sites to a cardiomyocyte-restricted microRNA within the 3&#39; untranslated region of the expression cassette that limits expression to nonmyocytes. After optimizing this expression cassette to reprogram human cardiac fibroblasts into induced cardiomyocyte-like cells in vitro, we also tested the ability of this capsid/cassette combination to confer functional benefit in acute mouse myocardial infarction and chronic rat myocardial infarction models. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We demonstrated sustained, dose-dependent improvement in cardiac function when treating a rat model 2 weeks after myocardial infarction, showing that cardiac reprogramming, when delivered in a single, clinically relevant adeno-associated virus vector, can support functional improvement in the postremodeled heart. This benefit was not observed with GFP (green fluorescent protein) or a hepatocyte reprogramming cocktail and was achieved even in the presence of immunosuppression, supporting myocyte formation as the underlying mechanism. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Collectively, these results advance the application of cardiac reprogramming gene therapy as a viable therapeutic approach to treat chronic heart failure resulting from ischemic injury.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37602409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37602409</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061542>10.1161/CIRCULATIONAHA.122.061542</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37602409</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Huanyu Zhou</dc:creator><dc:creator> Jin Yang</dc:creator><dc:creator> Chetan Srinath</dc:creator><dc:creator> Aliya Zeng</dc:creator><dc:creator> Iris Wu</dc:creator><dc:creator> Elena C Leon</dc:creator><dc:creator> Tawny Neal Qureshi</dc:creator><dc:creator> Christopher A Reid</dc:creator><dc:creator> Emily R Nettesheim</dc:creator><dc:creator> Emma Xu</dc:creator><dc:creator> Zoe Duclos</dc:creator><dc:creator> Tamer MA Mohamed</dc:creator><dc:creator> Farshad Farshidfar</dc:creator><dc:creator> Anthony Fejes</dc:creator><dc:creator> Jun Liu</dc:creator><dc:creator> Samantha Jones</dc:creator><dc:creator> Charles Feathers</dc:creator><dc:creator> Tae Won Chung</dc:creator><dc:creator> Frank Jing</dc:creator><dc:creator> William S Prince</dc:creator><dc:creator> JianMin Lin</dc:creator><dc:creator> Pengzhi Yu</dc:creator><dc:creator> Deepak Srivastava</dc:creator><dc:creator> Timothy Hoey</dc:creator><dc:creator> Kathryn N Ivey</dc:creator><dc:creator> Laura M Lombardi</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> Circulation</dc:source><dc:title> Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus</dc:title><dc:identifier> pmid:37602409</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.061542</dc:identifier></item><item><title> Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823081430&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 21. doi: 10.1161/CIRCULATIONAHA.123.065770. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >;96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; <i>P</i> =0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; <i>P</i> =0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; <i>P</i> =0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; <i>P</i> =0.02). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> REGISTRATION: URL: https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICALTRIALS: gov; Unique identifier: NCT02100722.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37602376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37602376</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065770>10.1161/CIRCULATIONAHA.123.065770</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37602376</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Frederik M Zimmermann</dc:creator><dc:creator> Victoria Y Ding</dc:creator><dc:creator> Nico HJ Pijls</dc:creator><dc:creator> Zsolt Piroth</dc:creator><dc:creator> Albert HM van Straten</dc:creator><dc:creator> Laszlo Szekely</dc:creator><dc:creator> Giedrius Davidavicius</dc:creator><dc:creator> Gintaras Kalinauskas</dc:creator><dc:creator> Samer Mansour</dc:creator><dc:creator> Rajesh Kharbanda</dc:creator><dc:creator> Nikolaos Östlund-Papadogeorgos</dc:creator><dc:creator> Adel Aminian</dc:creator><dc:creator> Keith G Oldroyd</dc:creator><dc:creator> Nawwar Al-Attar</dc:creator><dc:creator> Nikola Jagic</dc:creator><dc:creator> Jan-Henk E Dambrink</dc:creator><dc:creator> Petr Kala</dc:creator><dc:creator> Oskar Angeras</dc:creator><dc:creator> Philip MacCarthy</dc:creator><dc:creator> Olaf Wendler</dc:creator><dc:creator> Filip Casselman</dc:creator><dc:creator> Nils Witt</dc:creator><dc:creator> Kreton Mavromatis</dc:creator><dc:creator> Steven ES Miner</dc:creator><dc:creator> Jaydeep Sarma</dc:creator><dc:creator> Thomas Engstrøm</dc:creator><dc:creator> Evald H Christiansen</dc:creator><dc:creator> Pim AL Tonino</dc:creator><dc:creator> Michael J Reardon</dc:creator><dc:creator> Hisao Otsuki</dc:creator><dc:creator> Yuhei Kobayashi</dc:creator><dc:creator> Mark A Hlatky</dc:creator><dc:creator> Kenneth W Mahaffey</dc:creator><dc:creator> Manisha Desai</dc:creator><dc:creator> Y Joseph Woo</dc:creator><dc:creator> Alan C Yeung</dc:creator><dc:creator> Bernard De Bruyne</dc:creator><dc:creator> William F Fearon</dc:creator><dc:creator> FAME 3 Investigators</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> Circulation</dc:source><dc:title> Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial</dc:title><dc:identifier> pmid:37602376</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065770</dc:identifier></item><item><title> Epilepsy and long-term risk of arrhythmias</title><link/> https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823081430&amp;v=2.17.9.post6+86293ac<description> CONCLUSION: This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid. These findings highlight the need for regular heart rhythm monitoring and management in people with epilepsy in order to reduce the risk of further cardiovascular complications. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 21:ehad523. doi: 10.1093/eurheartj/ehad523. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Previous evidence has mainly supported transient changes in cardiac function during interictal or peri-ictal phases in people with epilepsy, but the long-term risk of cardiac arrhythmias is poorly described. This study aimed to assess the long-term association of epilepsy with cardiac arrhythmias, considering the potential role of genetic predisposition and antiseizure medications (ASMs) in any associations observed. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This population-based study evaluated UK Biobank data for individuals recruited between 2006 and 2010. Cox proportional hazards models and competing risk models were used to examine the association of epilepsy history with the long-term incidence risk of cardiac arrhythmias and arrhythmias subtypes. Polygenic risk scores (PRS) were calculated to investigate the effect of genetic susceptibility. The role of ASMs was also evaluated by integrating observational and drug target Mendelian randomization (MR) evidence. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The study included 329 432 individuals, including 2699 people with epilepsy. Compared with those without epilepsy, people with epilepsy experienced an increased risk of all cardiac arrhythmias [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.21-1.53], atrial fibrillation (HR 1.26, 95% CI 1.08-1.46), and other cardiac arrhythmias (HR 1.56, 95% CI 1.34-1.81). The associations were not modified by genetic predisposition as indicated by PRS. Competing and sensitivity analyses corroborated these results. Individuals with epilepsy using ASMs, especially carbamazepine and valproic acid, were at a higher risk for cardiac arrhythmias. This observation was further supported by drug target MR results (PSMR &lt; .05 and PHEIDI >; .05). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid. These findings highlight the need for regular heart rhythm monitoring and management in people with epilepsy in order to reduce the risk of further cardiovascular complications.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37602368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37602368</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad523>10.1093/eurheartj/ehad523</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37602368</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jie Wang</dc:creator><dc:creator> Peiyuan Huang</dc:creator><dc:creator> Qingwei Yu</dc:creator><dc:creator> Jun Lu</dc:creator><dc:creator> Pinbo Liu</dc:creator><dc:creator> Yiping Yang</dc:creator><dc:creator> Zeying Feng</dc:creator><dc:creator> Jingjing Cai</dc:creator><dc:creator> Guoping Yang</dc:creator><dc:creator> Hong Yuan</dc:creator><dc:creator> Haibo Tang</dc:creator><dc:creator> Yao Lu</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> European heart journal</dc:source><dc:title> Epilepsy and long-term risk of arrhythmias</dc:title><dc:identifier> pmid:37602368</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad523</dc:identifier></item><item><title> Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</title><link/> https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823081430&amp;v=2.17.9.post6+86293ac<description> Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 21:ehad484. doi: 10.1093/eurheartj/ehad484. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this position paper, the state-of-the-art knowledge of various AT depots is reviewed providing a consensus definition of PVAT around the coronary arteries, as the AT surrounding the artery up to a distance from its outer wall equal to the luminal diameter of the artery. Special focus is given to the interactions between PVAT and the vascular wall that render PVAT a potential therapeutic target in cardiovascular diseases. This Clinical Consensus Statement also discusses the role of PVAT as a clinically relevant source of diagnostic and prognostic biomarkers of vascular function, which may guide precision medicine in atherosclerosis, hypertension, heart failure, and other cardiovascular diseases. In this article, its role as a &#39;biosensor&#39; of vascular inflammation is highlighted with description of recent imaging technologies that visualize PVAT in clinical practice, allowing non-invasive quantification of coronary inflammation and the related residual cardiovascular inflammatory risk, guiding deployment of therapeutic interventions. Finally, the current and future clinical applicability of artificial intelligence and machine learning technologies is reviewed that integrate PVAT information into prognostic models to provide clinically meaningful information in primary and secondary prevention.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37599464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37599464</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad484>10.1093/eurheartj/ehad484</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37599464</guid><pubDate> Mon, 21 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Charalambos Antoniades</dc:creator><dc:creator> Dimitris Tousoulis</dc:creator><dc:creator> Marija Vavlukis</dc:creator><dc:creator> Ingrid Fleming</dc:creator><dc:creator> Dirk J Duncker</dc:creator><dc:creator> Etto Eringa</dc:creator><dc:creator> Olivia Manfrini</dc:creator><dc:creator> Alexios S Antonopoulos</dc:creator><dc:creator> Evangelos Oikonomou</dc:creator><dc:creator> Teresa Padró</dc:creator><dc:creator> Danijela Trifunovic-Zamaklar</dc:creator><dc:creator> Giuseppe De Luca</dc:creator><dc:creator> Tomasz Guzik</dc:creator><dc:creator> Edina Cenko</dc:creator><dc:creator> Ana Djordjevic-Dikic</dc:creator><dc:creator> Filippo Crea</dc:creator><dc:date> 2023-08-21</dc:date><dc:source> European heart journal</dc:source><dc:title> Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers</dc:title><dc:identifier> pmid:37599464</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad484</dc:identifier></item><item><title> Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</title><link/> https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823081430&amp;v=2.17.9.post6+86293ac<description> Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 15:S0092-8674(23)00796-1. doi: 10.1016/j.cell.2023.07.019. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Inflammation can trigger lasting phenotypes in immune and non-immune cells. Whether and how human infections and associated inflammation can form innate immune memory in hematopoietic stem and progenitor cells (HSPC) has remained unclear. We found that circulating HSPC, enriched from peripheral blood, captured the diversity of bone marrow HSPC, enabling investigation of their epigenomic reprogramming following coronavirus disease 2019 (COVID-19). Alterations in innate immune phenotypes and epigenetic programs of HSPC persisted for months to 1 year following severe COVID-19 and were associated with distinct transcription factor (TF) activities, altered regulation of inflammatory programs, and durable increases in myelopoiesis. HSPC epigenomic alterations were conveyed, through differentiation, to progeny innate immune cells. Early activity of IL-6 contributed to these persistent phenotypes in human COVID-19 and a mouse coronavirus infection model. Epigenetic reprogramming of HSPC may underlie altered immune function following infection and be broadly relevant, especially for millions of COVID-19 survivors.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37597510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37597510</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.019>10.1016/j.cell.2023.07.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37597510</guid><pubDate> Sat, 19 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jin-Gyu Cheong</dc:creator><dc:creator> Arjun Ravishankar</dc:creator><dc:creator> Siddhartha Sharma</dc:creator><dc:creator> Christopher N Parkhurst</dc:creator><dc:creator> Simon A Grassmann</dc:creator><dc:creator> Claire K Wingert</dc:creator><dc:creator> Paoline Laurent</dc:creator><dc:creator> Sai Ma</dc:creator><dc:creator> Lucinda Paddock</dc:creator><dc:creator> Isabella C Miranda</dc:creator><dc:creator> Emin Onur Karakaslar</dc:creator><dc:creator> Djamel Nehar-Belaid</dc:creator><dc:creator> Asa Thibodeau</dc:creator><dc:creator> Michael J Bale</dc:creator><dc:creator> Vinay K Kartha</dc:creator><dc:creator> Jim K Yee</dc:creator><dc:creator> Minh Y Mays</dc:creator><dc:creator> Chenyang Jiang</dc:creator><dc:creator> Andrew W Daman</dc:creator><dc:creator> Alexia Martinez de Paz</dc:creator><dc:creator> Dughan Ahimovic</dc:creator><dc:creator> Victor Ramos</dc:creator><dc:creator> Alexander Lercher</dc:creator><dc:creator> Erik Nielsen</dc:creator><dc:creator> Sergio Alvarez-Mulett</dc:creator><dc:creator> Ling Zheng</dc:creator><dc:creator> Andrew Earl</dc:creator><dc:creator> Alisha Yallowitz</dc:creator><dc:creator> Lexi Robbins</dc:creator><dc:creator> Elyse LaFond</dc:creator><dc:creator> Karissa L Weidman</dc:creator><dc:creator> Sabrina Racine-Brzostek</dc:creator><dc:creator> He S Yang</dc:creator><dc:creator> David R Price</dc:creator><dc:creator> Louise Leyre</dc:creator><dc:creator> André F Rendeiro</dc:creator><dc:creator> Hiranmayi Ravichandran</dc:creator><dc:creator> Junbum Kim</dc:creator><dc:creator> Alain C Borczuk</dc:creator><dc:creator> Charles M Rice</dc:creator><dc:creator> R Brad Jones</dc:creator><dc:creator> Edward J Schenck</dc:creator><dc:creator> Robert J Kaner</dc:creator><dc:creator> Amy Chadburn</dc:creator><dc:creator> Zhen Zhao</dc:creator><dc:creator> Virginia Pascual</dc:creator><dc:creator> Olivier Elemento</dc:creator><dc:creator> Robert E Schwartz</dc:creator><dc:creator> Jason D Buenrostro</dc:creator><dc:creator> Rachel E Niec</dc:creator><dc:creator> Franck J Barrat</dc:creator><dc:creator> Lindsay Lief</dc:creator><dc:creator> Joseph C Sun</dc:creator><dc:creator> Duygu Ucar</dc:creator><dc:creator> Steven Z Josefowicz</dc:creator><dc:date> 2023-08-19</dc:date><dc:source> Cell</dc:source><dc:title> Epigenetic memory of coronavirus infection in innate immune cells and their progenitors</dc:title><dc:identifier> pmid:37597510</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.019</dc:identifier></item><item><title> Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</title><link/> https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823081430&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 19:ehad527. doi: 10.1093/eurheartj/ehad527. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37596979/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823081430&v=2.17.9.post6+86293ac">37596979</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad527>10.1093/eurheartj/ehad527</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37596979</guid><pubDate> Sat, 19 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Steven E Nissen</dc:creator><dc:date> 2023-08-19</dc:date><dc:source> European heart journal</dc:source><dc:title> Plaque morphology, inflammation, and outcome: cautious and tempered interpretation warranted</dc:title><dc:identifier> pmid:37596979</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad527</dc:identifier></item></channel></rss>